Business Wire

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life

Jaa

Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/

During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients

During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients

Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 schools, six universities, eight partners, in addition to 37 institutions from the public and private sectors and 67 cancer survivors.

Included in the programme for the 24 hours was an extensive array of activities in a kids’ fun area, a ‘Luminaria’ candle illumination event to remember loved ones who had died of cancer and a ‘Survivors’ Tent’ that saw a number of those who had defeated the disease address audiences. Participants’ hunger was kept assuaged by a host of food and refreshment stands, all of which donated their proceeds to FoCP.

The first UAE RFL was launched by Sheikha Jawaher Al Qasimi, Founder and Royal Patron of FoCP, International Ambassador of the World Cancer Declaration for the Union for International Cancer Control (UICC) and International Ambassador for Childhood Cancer for UICC. Her Highness joined cancer survivors in the first lap of the walkathon, highlighting the importance of raising awareness of the disease and the necessity of screening for its early detection – the most important factor in survival and recovery.

The 24 hour nature of RFL is designed to highlight that cancer is a disease that doesn’t sleep and to show solidarity with cancer patients who can feel a sense of loneliness during the small hours.

RFL has its roots in the USA when in 1985 Dr. Gordon Klatt, a colorectal surgeon, raised $27,000 for his local cancer charity by walking for 24 hours. The event currently takes place in 29 countries, with the UAE the most recent addition to the global network. To date RFL raised more than $5 billion in support of cancer patients worldwide.

Contact information

National Network Communications (NNC)
Maha Abou Rich, +971503417775

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 16:33Tiedote

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 16:00Tiedote

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer

CTS Engines Announces Senior Management Hire12.12.2017 16:00Tiedote

CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4

LTI to Offer Blockchain Solution Powered by Microsoft Azure12.12.2017 13:45Tiedote

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, announced today the availability of its blockchain-based trade finance solution on Microsoft Azure marketplace. The solution tracks the flow of goods in a value chain, improving transparency across multiple entities involved. It enables accelerated adoption of distributed ledger technologies by bringing together LTI’s deep industry knowledge and blockchain capabilities together with Microsoft’s expertise in cloud-based solutions. Aftab Ullah, Chief Operating Officer, LTI said, "Our vision is to deliver exponential operational efficiencies to the world’s leading companies through digital innovation. LTI’s Blockchain services include end-to-end consulting and implementation and are designed to help transform our clients’ business operations. The collaboration

Munich Re Automation Solutions Ltd. today announced the launch of their latest data analytics and reporting product, ALLFINANZ Insight12.12.2017 12:06Tiedote

Munich Re Automation Solutions Ltd., the leading provider of digital underwriting solutions to the life insurance industry, today announced the launch of their latest data analytics and reporting product, ALLFINANZ Insight. ALLFINANZ Insight is designed to help life insurance companies unlock the insights hidden in their underwriting data using a creative and intuitive interface and 30 years of underwriting expertise built in. A vast amount of data is captured during the new business and underwriting process. Accurately categorising and understanding this data can be hugely valuable as the insights generated will significantly improve the design of underwriting rules, the new business and underwriting process as well as operations and distribution management. ALLFINANZ Insight gives your whole team a clearer, deeper view into their underwriting data. The software uses cutt

New Data for Darzalex®▼(daratumumab) Presented at ASH 2017 Show Feasibility of Subcutaneous Use and Potential of Darzalex as a Treatment for Smouldering Multiple Myeloma12.12.2017 11:00Tiedote

Janssen-Cilag International NV (“Janssen”) today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of Darzalex® (daratumumab) co-formulated with recombinant human hyaluronidase enzyme (daratumumab-SC), was generally well-tolerated, with a 12 percent rate of infusion-related reactions (IRRs), in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta. Daratumumab is currently approved for intravenous (IV) administration, and results from the PAVO trial serve as the basis for an actively enrolling Phase 3 study comparing subcutaneous administration of daratumumab over 3-5 minutes with the approved IV administration in relapsed and refractory multiple myeloma patients.2 Daratumumab is currently indica

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme